menu ☰
menu ˟

Bioventus announces agreement to continue distribution of five-injection HA product for knee OA

18 Feb 2018
Bioventus announced it has extended its agreement with Seikagaku Corporation to continue distributing the five-injection, hyaluronic acid product Supartz FX in the United States until May 2028.According to a press release Bioventus will be the exclus...

Click here to view the full article which appeared in Rheumatology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.